nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—metabolic syndrome X	0.477	0.678	CbGaD
Thalidomide—PTGS2—metabolic syndrome X	0.227	0.322	CbGaD
Thalidomide—Anaemia megaloblastic—Metformin—metabolic syndrome X	0.00606	0.095	CcSEcCtD
Thalidomide—Pomalidomide—TNF—metabolic syndrome X	0.00288	0.504	CrCbGaD
Thalidomide—NFKB1—cardiovascular system—metabolic syndrome X	0.00254	0.0661	CbGeAlD
Thalidomide—NFKB1—kidney—metabolic syndrome X	0.00249	0.0647	CbGeAlD
Thalidomide—Toothache—Metformin—metabolic syndrome X	0.00235	0.0368	CcSEcCtD
Thalidomide—NFKB1—adipose tissue—metabolic syndrome X	0.00224	0.0583	CbGeAlD
Thalidomide—Nail disorder—Metformin—metabolic syndrome X	0.0022	0.0345	CcSEcCtD
Thalidomide—FGFR2—cardiovascular system—metabolic syndrome X	0.00191	0.0496	CbGeAlD
Thalidomide—CRBN—adipose tissue—metabolic syndrome X	0.00188	0.0488	CbGeAlD
Thalidomide—FGFR2—kidney—metabolic syndrome X	0.00187	0.0486	CbGeAlD
Thalidomide—PTGS1—artery—metabolic syndrome X	0.00175	0.0454	CbGeAlD
Thalidomide—Blood disorder—Metformin—metabolic syndrome X	0.00171	0.0268	CcSEcCtD
Thalidomide—FGFR2—adipose tissue—metabolic syndrome X	0.00169	0.0438	CbGeAlD
Thalidomide—PTGS2—artery—metabolic syndrome X	0.00167	0.0434	CbGeAlD
Thalidomide—Accidental injury—Metformin—metabolic syndrome X	0.00161	0.0253	CcSEcCtD
Thalidomide—NFKB1—liver—metabolic syndrome X	0.00157	0.0409	CbGeAlD
Thalidomide—PTGS1—endothelium—metabolic syndrome X	0.00148	0.0384	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—metabolic syndrome X	0.00147	0.257	CrCbGaD
Thalidomide—PTGS2—endothelium—metabolic syndrome X	0.00141	0.0367	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—metabolic syndrome X	0.00137	0.239	CrCbGaD
Thalidomide—PTGS1—blood vessel—metabolic syndrome X	0.00136	0.0354	CbGeAlD
Thalidomide—Neuropathy—Metformin—metabolic syndrome X	0.00134	0.021	CcSEcCtD
Thalidomide—CRBN—liver—metabolic syndrome X	0.00132	0.0343	CbGeAlD
Thalidomide—PTGS2—blood vessel—metabolic syndrome X	0.0013	0.0338	CbGeAlD
Thalidomide—Lightheadedness—Metformin—metabolic syndrome X	0.00128	0.02	CcSEcCtD
Thalidomide—FGFR2—liver—metabolic syndrome X	0.00118	0.0307	CbGeAlD
Thalidomide—Injury—Metformin—metabolic syndrome X	0.00113	0.0177	CcSEcCtD
Thalidomide—Hypoglycaemia—Metformin—metabolic syndrome X	0.00106	0.0167	CcSEcCtD
Thalidomide—Lethargy—Metformin—metabolic syndrome X	0.00106	0.0166	CcSEcCtD
Thalidomide—Pain in extremity—Metformin—metabolic syndrome X	0.00104	0.0163	CcSEcCtD
Thalidomide—Migraine—Metformin—metabolic syndrome X	0.00102	0.016	CcSEcCtD
Thalidomide—Dehydration—Metformin—metabolic syndrome X	0.000963	0.0151	CcSEcCtD
Thalidomide—Liver function test abnormal—Metformin—metabolic syndrome X	0.000956	0.015	CcSEcCtD
Thalidomide—Breast disorder—Metformin—metabolic syndrome X	0.000936	0.0147	CcSEcCtD
Thalidomide—Cramp muscle—Metformin—metabolic syndrome X	0.000933	0.0146	CcSEcCtD
Thalidomide—Abdominal distension—Metformin—metabolic syndrome X	0.000901	0.0141	CcSEcCtD
Thalidomide—Influenza—Metformin—metabolic syndrome X	0.000895	0.014	CcSEcCtD
Thalidomide—Pancreatitis—Metformin—metabolic syndrome X	0.000878	0.0138	CcSEcCtD
Thalidomide—Angina pectoris—Metformin—metabolic syndrome X	0.000872	0.0137	CcSEcCtD
Thalidomide—Neutropenia—Metformin—metabolic syndrome X	0.000837	0.0131	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.000832	0.0131	CcSEcCtD
Thalidomide—Infestation—Metformin—metabolic syndrome X	0.000798	0.0125	CcSEcCtD
Thalidomide—Infestation NOS—Metformin—metabolic syndrome X	0.000798	0.0125	CcSEcCtD
Thalidomide—Drowsiness—Metformin—metabolic syndrome X	0.000798	0.0125	CcSEcCtD
Thalidomide—Neuropathy peripheral—Metformin—metabolic syndrome X	0.000782	0.0123	CcSEcCtD
Thalidomide—Bradycardia—Metformin—metabolic syndrome X	0.000729	0.0114	CcSEcCtD
Thalidomide—Rhinitis—Metformin—metabolic syndrome X	0.000718	0.0113	CcSEcCtD
Thalidomide—Hepatitis—Metformin—metabolic syndrome X	0.000717	0.0112	CcSEcCtD
Thalidomide—Hypoaesthesia—Metformin—metabolic syndrome X	0.000713	0.0112	CcSEcCtD
Thalidomide—Oedema peripheral—Metformin—metabolic syndrome X	0.000706	0.0111	CcSEcCtD
Thalidomide—CYP1A1—kidney—metabolic syndrome X	0.000677	0.0176	CbGeAlD
Thalidomide—Eye disorder—Metformin—metabolic syndrome X	0.00067	0.0105	CcSEcCtD
Thalidomide—CYP2C9—cardiovascular system—metabolic syndrome X	0.000666	0.0173	CbGeAlD
Thalidomide—Cardiac disorder—Metformin—metabolic syndrome X	0.000665	0.0104	CcSEcCtD
Thalidomide—CYP3A5—kidney—metabolic syndrome X	0.000662	0.0172	CbGeAlD
Thalidomide—Angiopathy—Metformin—metabolic syndrome X	0.00065	0.0102	CcSEcCtD
Thalidomide—Immune system disorder—Metformin—metabolic syndrome X	0.000647	0.0102	CcSEcCtD
Thalidomide—Mediastinal disorder—Metformin—metabolic syndrome X	0.000646	0.0101	CcSEcCtD
Thalidomide—Chills—Metformin—metabolic syndrome X	0.000643	0.0101	CcSEcCtD
Thalidomide—CYP2E1—cardiovascular system—metabolic syndrome X	0.000631	0.0164	CbGeAlD
Thalidomide—Malnutrition—Metformin—metabolic syndrome X	0.000624	0.00979	CcSEcCtD
Thalidomide—CYP2E1—kidney—metabolic syndrome X	0.000617	0.016	CbGeAlD
Thalidomide—Flatulence—Metformin—metabolic syndrome X	0.000615	0.00964	CcSEcCtD
Thalidomide—Dysgeusia—Metformin—metabolic syndrome X	0.000611	0.00958	CcSEcCtD
Thalidomide—CYP1A1—adipose tissue—metabolic syndrome X	0.00061	0.0158	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—metabolic syndrome X	0.000608	0.0158	CbGeAlD
Thalidomide—Muscle spasms—Metformin—metabolic syndrome X	0.0006	0.00941	CcSEcCtD
Thalidomide—CYP3A5—adipose tissue—metabolic syndrome X	0.000596	0.0155	CbGeAlD
Thalidomide—PTGS1—kidney—metabolic syndrome X	0.000595	0.0154	CbGeAlD
Thalidomide—Vision blurred—Metformin—metabolic syndrome X	0.000588	0.00922	CcSEcCtD
Thalidomide—Tremor—Metformin—metabolic syndrome X	0.000584	0.00917	CcSEcCtD
Thalidomide—PTGS2—cardiovascular system—metabolic syndrome X	0.000581	0.0151	CbGeAlD
Thalidomide—Ill-defined disorder—Metformin—metabolic syndrome X	0.000579	0.00908	CcSEcCtD
Thalidomide—PTGS2—kidney—metabolic syndrome X	0.000568	0.0148	CbGeAlD
Thalidomide—Malaise—Metformin—metabolic syndrome X	0.000562	0.00883	CcSEcCtD
Thalidomide—Syncope—Metformin—metabolic syndrome X	0.000559	0.00878	CcSEcCtD
Thalidomide—Palpitations—Metformin—metabolic syndrome X	0.000551	0.00865	CcSEcCtD
Thalidomide—Loss of consciousness—Metformin—metabolic syndrome X	0.000548	0.0086	CcSEcCtD
Thalidomide—Hypertension—Metformin—metabolic syndrome X	0.000539	0.00845	CcSEcCtD
Thalidomide—PTGS1—adipose tissue—metabolic syndrome X	0.000536	0.0139	CbGeAlD
Thalidomide—Chest pain—Metformin—metabolic syndrome X	0.000531	0.00833	CcSEcCtD
Thalidomide—Myalgia—Metformin—metabolic syndrome X	0.000531	0.00833	CcSEcCtD
Thalidomide—CYP2C19—liver—metabolic syndrome X	0.000531	0.0138	CbGeAlD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000527	0.00828	CcSEcCtD
Thalidomide—Discomfort—Metformin—metabolic syndrome X	0.000525	0.00823	CcSEcCtD
Thalidomide—PTGS2—adipose tissue—metabolic syndrome X	0.000512	0.0133	CbGeAlD
Thalidomide—Oedema—Metformin—metabolic syndrome X	0.000509	0.00799	CcSEcCtD
Thalidomide—Infection—Metformin—metabolic syndrome X	0.000506	0.00794	CcSEcCtD
Thalidomide—Shock—Metformin—metabolic syndrome X	0.000501	0.00786	CcSEcCtD
Thalidomide—Nervous system disorder—Metformin—metabolic syndrome X	0.000499	0.00783	CcSEcCtD
Thalidomide—Thrombocytopenia—Metformin—metabolic syndrome X	0.000498	0.00782	CcSEcCtD
Thalidomide—Skin disorder—Metformin—metabolic syndrome X	0.000494	0.00776	CcSEcCtD
Thalidomide—Hyperhidrosis—Metformin—metabolic syndrome X	0.000492	0.00772	CcSEcCtD
Thalidomide—Anorexia—Metformin—metabolic syndrome X	0.000485	0.00761	CcSEcCtD
Thalidomide—Hypotension—Metformin—metabolic syndrome X	0.000476	0.00746	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000464	0.00728	CcSEcCtD
Thalidomide—Paraesthesia—Metformin—metabolic syndrome X	0.000457	0.00717	CcSEcCtD
Thalidomide—Dyspnoea—Metformin—metabolic syndrome X	0.000454	0.00712	CcSEcCtD
Thalidomide—Somnolence—Metformin—metabolic syndrome X	0.000453	0.0071	CcSEcCtD
Thalidomide—Dyspepsia—Metformin—metabolic syndrome X	0.000448	0.00703	CcSEcCtD
Thalidomide—Decreased appetite—Metformin—metabolic syndrome X	0.000443	0.00694	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000439	0.0069	CcSEcCtD
Thalidomide—Fatigue—Metformin—metabolic syndrome X	0.000439	0.00689	CcSEcCtD
Thalidomide—Constipation—Metformin—metabolic syndrome X	0.000435	0.00683	CcSEcCtD
Thalidomide—CYP1A2—liver—metabolic syndrome X	0.000434	0.0113	CbGeAlD
Thalidomide—CYP1A1—liver—metabolic syndrome X	0.000428	0.0111	CbGeAlD
Thalidomide—Feeling abnormal—Metformin—metabolic syndrome X	0.000419	0.00658	CcSEcCtD
Thalidomide—CYP3A5—liver—metabolic syndrome X	0.000418	0.0109	CbGeAlD
Thalidomide—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000416	0.00653	CcSEcCtD
Thalidomide—CYP2C9—liver—metabolic syndrome X	0.000412	0.0107	CbGeAlD
Thalidomide—Urticaria—Metformin—metabolic syndrome X	0.000404	0.00635	CcSEcCtD
Thalidomide—Abdominal pain—Metformin—metabolic syndrome X	0.000402	0.00631	CcSEcCtD
Thalidomide—CYP2E1—liver—metabolic syndrome X	0.00039	0.0101	CbGeAlD
Thalidomide—Asthenia—Metformin—metabolic syndrome X	0.000365	0.00573	CcSEcCtD
Thalidomide—Pruritus—Metformin—metabolic syndrome X	0.00036	0.00565	CcSEcCtD
Thalidomide—PTGS2—liver—metabolic syndrome X	0.000359	0.00933	CbGeAlD
Thalidomide—Diarrhoea—Metformin—metabolic syndrome X	0.000348	0.00547	CcSEcCtD
Thalidomide—Dizziness—Metformin—metabolic syndrome X	0.000337	0.00528	CcSEcCtD
Thalidomide—Vomiting—Metformin—metabolic syndrome X	0.000324	0.00508	CcSEcCtD
Thalidomide—Rash—Metformin—metabolic syndrome X	0.000321	0.00504	CcSEcCtD
Thalidomide—Dermatitis—Metformin—metabolic syndrome X	0.000321	0.00503	CcSEcCtD
Thalidomide—Headache—Metformin—metabolic syndrome X	0.000319	0.005	CcSEcCtD
Thalidomide—Nausea—Metformin—metabolic syndrome X	0.000302	0.00474	CcSEcCtD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.49e-05	7.92e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT2—metabolic syndrome X	1.48e-05	7.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMGCR—metabolic syndrome X	1.48e-05	7.89e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SCARB1—metabolic syndrome X	1.48e-05	7.87e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT2—metabolic syndrome X	1.48e-05	7.87e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMGCR—metabolic syndrome X	1.48e-05	7.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TRIB3—metabolic syndrome X	1.47e-05	7.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	1.46e-05	7.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS1—metabolic syndrome X	1.46e-05	7.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G6—metabolic syndrome X	1.46e-05	7.75e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOB—metabolic syndrome X	1.45e-05	7.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.45e-05	7.7e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA5—metabolic syndrome X	1.44e-05	7.67e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.44e-05	7.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—metabolic syndrome X	1.44e-05	7.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SREBF1—metabolic syndrome X	1.44e-05	7.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	1.42e-05	7.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—metabolic syndrome X	1.42e-05	7.56e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G4A—metabolic syndrome X	1.41e-05	7.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCA1—metabolic syndrome X	1.4e-05	7.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A4—metabolic syndrome X	1.4e-05	7.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.4e-05	7.45e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—metabolic syndrome X	1.4e-05	7.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—INS—metabolic syndrome X	1.4e-05	7.45e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	1.4e-05	7.44e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMGCR—metabolic syndrome X	1.4e-05	7.43e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT2—metabolic syndrome X	1.4e-05	7.43e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LPL—metabolic syndrome X	1.39e-05	7.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS1—metabolic syndrome X	1.39e-05	7.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOB—metabolic syndrome X	1.38e-05	7.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—metabolic syndrome X	1.38e-05	7.33e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.37e-05	7.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—metabolic syndrome X	1.36e-05	7.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GOT1—metabolic syndrome X	1.36e-05	7.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GGT1—metabolic syndrome X	1.36e-05	7.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.36e-05	7.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—metabolic syndrome X	1.35e-05	7.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—G6PD—metabolic syndrome X	1.35e-05	7.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TRIB3—metabolic syndrome X	1.34e-05	7.13e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	1.33e-05	7.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—INS—metabolic syndrome X	1.33e-05	7.06e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A4—metabolic syndrome X	1.32e-05	7.03e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCA1—metabolic syndrome X	1.32e-05	7.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAMPT—metabolic syndrome X	1.32e-05	7.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A4—metabolic syndrome X	1.32e-05	7.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCA1—metabolic syndrome X	1.32e-05	7.01e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CD36—metabolic syndrome X	1.32e-05	7.01e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HDAC3—metabolic syndrome X	1.31e-05	7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LPL—metabolic syndrome X	1.31e-05	7e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.31e-05	6.98e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LIPC—metabolic syndrome X	1.31e-05	6.97e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCK—metabolic syndrome X	1.31e-05	6.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—metabolic syndrome X	1.31e-05	6.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOC3—metabolic syndrome X	1.3e-05	6.93e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—metabolic syndrome X	1.29e-05	6.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPA—metabolic syndrome X	1.28e-05	6.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCKR—metabolic syndrome X	1.28e-05	6.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—metabolic syndrome X	1.28e-05	6.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—metabolic syndrome X	1.28e-05	6.83e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT1—metabolic syndrome X	1.28e-05	6.81e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT1—metabolic syndrome X	1.28e-05	6.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT1—metabolic syndrome X	1.28e-05	6.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT1—metabolic syndrome X	1.28e-05	6.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CETP—metabolic syndrome X	1.26e-05	6.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.26e-05	6.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCA1—metabolic syndrome X	1.24e-05	6.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A4—metabolic syndrome X	1.24e-05	6.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G6—metabolic syndrome X	1.24e-05	6.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.24e-05	6.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA5—metabolic syndrome X	1.23e-05	6.56e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—metabolic syndrome X	1.23e-05	6.53e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARA—metabolic syndrome X	1.22e-05	6.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—metabolic syndrome X	1.22e-05	6.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SCARB1—metabolic syndrome X	1.21e-05	6.44e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT1—metabolic syndrome X	1.21e-05	6.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT1—metabolic syndrome X	1.21e-05	6.42e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAMPT—metabolic syndrome X	1.2e-05	6.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.2e-05	6.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.19e-05	6.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LIPC—metabolic syndrome X	1.19e-05	6.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCK—metabolic syndrome X	1.19e-05	6.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOC3—metabolic syndrome X	1.19e-05	6.32e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—metabolic syndrome X	1.19e-05	6.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.18e-05	6.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SREBF1—metabolic syndrome X	1.17e-05	6.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.17e-05	6.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—metabolic syndrome X	1.16e-05	6.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—metabolic syndrome X	1.16e-05	6.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.16e-05	6.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOB—metabolic syndrome X	1.15e-05	6.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CETP—metabolic syndrome X	1.15e-05	6.13e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—metabolic syndrome X	1.15e-05	6.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TRIB3—metabolic syndrome X	1.15e-05	6.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMGCR—metabolic syndrome X	1.14e-05	6.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT2—metabolic syndrome X	1.14e-05	6.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G4A—metabolic syndrome X	1.12e-05	5.97e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	1.1e-05	5.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—metabolic syndrome X	1.1e-05	5.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—metabolic syndrome X	1.1e-05	5.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—metabolic syndrome X	1.1e-05	5.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—metabolic syndrome X	1.09e-05	5.8e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOB—metabolic syndrome X	1.09e-05	5.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOB—metabolic syndrome X	1.08e-05	5.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.07e-05	5.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	1.07e-05	5.7e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G4A—metabolic syndrome X	1.06e-05	5.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G4A—metabolic syndrome X	1.05e-05	5.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—metabolic syndrome X	1.05e-05	5.57e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT2—metabolic syndrome X	1.04e-05	5.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	1.04e-05	5.55e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—metabolic syndrome X	1.04e-05	5.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—metabolic syndrome X	1.03e-05	5.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.03e-05	5.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAMPT—metabolic syndrome X	1.03e-05	5.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOB—metabolic syndrome X	1.02e-05	5.45e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.02e-05	5.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—metabolic syndrome X	1.02e-05	5.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCK—metabolic syndrome X	1.02e-05	5.43e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—metabolic syndrome X	1.02e-05	5.42e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A4—metabolic syndrome X	1.02e-05	5.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOC3—metabolic syndrome X	1.01e-05	5.4e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—metabolic syndrome X	1.01e-05	5.39e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4A—metabolic syndrome X	9.95e-06	5.3e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—metabolic syndrome X	9.93e-06	5.29e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—metabolic syndrome X	9.87e-06	5.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—metabolic syndrome X	9.87e-06	5.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—metabolic syndrome X	9.85e-06	5.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—metabolic syndrome X	9.85e-06	5.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS1—metabolic syndrome X	9.83e-06	5.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—metabolic syndrome X	9.82e-06	5.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—metabolic syndrome X	9.77e-06	5.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—metabolic syndrome X	9.72e-06	5.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—metabolic syndrome X	9.45e-06	5.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SCARB1—metabolic syndrome X	9.43e-06	5.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—metabolic syndrome X	9.42e-06	5.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—metabolic syndrome X	9.41e-06	5.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	9.4e-06	5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	9.29e-06	4.94e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	9.29e-06	4.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—metabolic syndrome X	9.28e-06	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—metabolic syndrome X	9.23e-06	4.91e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	9.18e-06	4.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SREBF1—metabolic syndrome X	9.16e-06	4.87e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—metabolic syndrome X	9.15e-06	4.87e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—metabolic syndrome X	9.13e-06	4.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—metabolic syndrome X	9.12e-06	4.85e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—metabolic syndrome X	9.1e-06	4.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—metabolic syndrome X	9e-06	4.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—metabolic syndrome X	9e-06	4.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—metabolic syndrome X	8.97e-06	4.77e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMGCR—metabolic syndrome X	8.91e-06	4.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—metabolic syndrome X	8.91e-06	4.74e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—metabolic syndrome X	8.86e-06	4.72e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—metabolic syndrome X	8.85e-06	4.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—metabolic syndrome X	8.72e-06	4.64e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—metabolic syndrome X	8.71e-06	4.63e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—metabolic syndrome X	8.69e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—metabolic syndrome X	8.67e-06	4.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—metabolic syndrome X	8.64e-06	4.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—metabolic syndrome X	8.63e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—metabolic syndrome X	8.59e-06	4.57e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—metabolic syndrome X	8.57e-06	4.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—metabolic syndrome X	8.37e-06	4.46e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—metabolic syndrome X	8.36e-06	4.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—metabolic syndrome X	8.28e-06	4.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—metabolic syndrome X	8.27e-06	4.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—metabolic syndrome X	8.25e-06	4.39e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—metabolic syndrome X	8.19e-06	4.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4A—metabolic syndrome X	8.14e-06	4.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—metabolic syndrome X	8.11e-06	4.32e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—metabolic syndrome X	8.09e-06	4.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—metabolic syndrome X	8.04e-06	4.28e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	8.03e-06	4.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—metabolic syndrome X	7.99e-06	4.26e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—metabolic syndrome X	7.96e-06	4.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—metabolic syndrome X	7.94e-06	4.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A4—metabolic syndrome X	7.94e-06	4.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—metabolic syndrome X	7.88e-06	4.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—metabolic syndrome X	7.7e-06	4.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—metabolic syndrome X	7.69e-06	4.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—metabolic syndrome X	7.69e-06	4.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—metabolic syndrome X	7.64e-06	4.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—metabolic syndrome X	7.63e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—metabolic syndrome X	7.6e-06	4.04e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—metabolic syndrome X	7.57e-06	4.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—metabolic syndrome X	7.55e-06	4.02e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	7.43e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—metabolic syndrome X	7.42e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—metabolic syndrome X	7.4e-06	3.94e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—metabolic syndrome X	7.29e-06	3.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—metabolic syndrome X	7.23e-06	3.85e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—metabolic syndrome X	7.13e-06	3.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—metabolic syndrome X	7.06e-06	3.76e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—metabolic syndrome X	7e-06	3.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—metabolic syndrome X	6.93e-06	3.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—metabolic syndrome X	6.91e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—metabolic syndrome X	6.84e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—metabolic syndrome X	6.8e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—metabolic syndrome X	6.79e-06	3.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—metabolic syndrome X	6.7e-06	3.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—metabolic syndrome X	6.62e-06	3.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—metabolic syndrome X	6.52e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—metabolic syndrome X	6.51e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—metabolic syndrome X	6.49e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—metabolic syndrome X	6.44e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—metabolic syndrome X	6.41e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4A—metabolic syndrome X	6.35e-06	3.38e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—metabolic syndrome X	6.24e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—metabolic syndrome X	6.23e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—metabolic syndrome X	6.13e-06	3.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—metabolic syndrome X	6.11e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—metabolic syndrome X	6.11e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—metabolic syndrome X	6.04e-06	3.21e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—metabolic syndrome X	5.95e-06	3.17e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—metabolic syndrome X	5.94e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—metabolic syndrome X	5.92e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—metabolic syndrome X	5.84e-06	3.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—metabolic syndrome X	5.8e-06	3.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—metabolic syndrome X	5.72e-06	3.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—metabolic syndrome X	5.64e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—metabolic syndrome X	5.61e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—metabolic syndrome X	5.5e-06	2.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—metabolic syndrome X	5.46e-06	2.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—metabolic syndrome X	5.35e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—metabolic syndrome X	5.33e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—metabolic syndrome X	5.32e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—metabolic syndrome X	5.25e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—metabolic syndrome X	5.22e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—metabolic syndrome X	5.22e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—metabolic syndrome X	5.16e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—metabolic syndrome X	5.02e-06	2.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—metabolic syndrome X	4.79e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—metabolic syndrome X	4.59e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—metabolic syndrome X	4.58e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—metabolic syndrome X	4.55e-06	2.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—metabolic syndrome X	4.46e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	4.19e-06	2.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—metabolic syndrome X	4.11e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—metabolic syndrome X	4.09e-06	2.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—metabolic syndrome X	4e-06	2.13e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—metabolic syndrome X	3.91e-06	2.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—metabolic syndrome X	3.79e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—metabolic syndrome X	3.58e-06	1.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—metabolic syndrome X	3.18e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—metabolic syndrome X	2.99e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—metabolic syndrome X	2.98e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—metabolic syndrome X	2.82e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—metabolic syndrome X	2.31e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—metabolic syndrome X	2.1e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—metabolic syndrome X	1.8e-06	9.57e-06	CbGpPWpGaD
